FHL5

FHL5 Full Name

four and a half LIM domains 5

FHL5 Introduction

Four and a half LIM domains 5 (FHL5), historically known as ACT (activator of cAMP-responsive element modulator in testis), is a specialized and versatile multi-functional scaffolding protein. Structurally, it is characterized by four complete LIM domains and a distinctive N-terminal half-LIM domain. Unlike typical transcription factors, these zinc-finger-like LIM domains do not bind DNA directly. Instead, they function as highly selective protein-protein interaction modules, enabling FHL5 to dock with various transcription factors and assemble potent, dynamic transcriptional complexes within the cell nucleus.

The canonical biological role of FHL5 is profoundly rooted in male reproductive physiology. FHL5 is predominantly expressed in post-meiotic male germ cells, specifically spermatids. In this unique microenvironment, it acts as a highly specific, phosphorylation-independent coactivator for the transcription factor CREM (cAMP-responsive element modulator). By directly interacting with CREM, FHL5 orchestrates the massive wave of gene transcription required for spermatid elongation, structural maturation, and ultimate differentiation into functional spermatozoa. Beyond reproductive biology, cutting-edge genome-wide association studies (GWAS) and epigenomic profiling have recently uncovered a critical, secondary role for FHL5 in the human cardiovascular system, where it heavily regulates complex gene networks in vascular smooth muscle cells (VSMCs).

Clinically, the dysregulation of FHL5 leads to vastly different pathologies depending on the tissue context. In the reproductive system, loss-of-function mutations or downregulations of FHL5 are directly associated with severe male infertility, predominantly manifesting as non-obstructive azoospermia and oligozoospermia due to arrested spermatogenesis. However, its most striking recent clinical associations lie in cardiovascular diseases. The FHL5 genetic locus (chr6q16.1) has been identified as a major risk variant for severe coronary artery disease (CAD), myocardial infarction, and hypertension. In these disease states, aberrant FHL5 expression drives pathological phenotypic switching in VSMCs—transforming them from a healthy, contractile state into an invasive, synthetic state that promotes aggressive vascular remodeling and atherosclerosis. Furthermore, emerging transcriptomic analyses suggest that FHL5 is differentially expressed in malignancies such as breast cancer, potentially influencing the tumor microenvironment. Consequently, FHL5 has transitioned from a niche reproductive gene to a highly valuable therapeutic target for life-threatening cardiovascular disorders.

Figure 1. Schematic depicting the proposed upstream and downstream mechanisms underlying the FHL5 genetic association with CAD/myocardial infarction (MI) and other vascular traits. (Source: Wong D, et al. 2023)

Alternate Names for FHL5

FHL5; four and a half LIM domains 5; ACT; dJ393D12.2; four and a half LIM domains protein 5; FHL-5; 1700027G07Rik; LIM protein ACT; activator of CREM in testis; activator of cAMP-responsive element modulator in testis; activator of cAMP-responsive element modulator (CREM) in testis;

• 1. Wong D, et al. FHL5 Controls Vascular Disease-Associated Gene Programs in Smooth Muscle Cells. Circ Res. 2023 Apr 28;132(9):1144-1161.
  2. Krausz C, et al. Genetic control of spermiogenesis: insights from the CREM gene and implications for human infertility. Reprod Biomed Online. 2005 Jan;10(1):64-71.